East Ocyon Bio: Pioneering Allogeneic Cell Therapy in India

Introduction

In 2026, the landscape of cancer treatment in India is set to transform with the innovative strides of East Ocyon Bio. Founded in Gurugram by Dinesh Kundu, Renu Kundu, and Narinder Mehra, the company is at the forefront of developing advanced cell therapies that promise to bridge the gap between global and domestic medical advancements.

Company Overview

East Ocyon Bio was established in 2022 with a mission to develop cutting-edge therapies for cancer, autoimmune disorders, and rare diseases in India and globally. The company's founders bring a wealth of expertise in medicine and business, with Dinesh Kundu holding an MBBS and MBA.

**Key Details: **

• Founded: 2022
• Founders: Dinesh Kundu, Renu Kundu, Narinder Mehra
• Headquarters: Gurugram
• Sector: Cell and gene therapy, oncology
• Funding Raised: ₹36 crore ($4.2 million), seed round (December 2024)
• Key Investors: Aeravti Ventures and Micro Labs
• Institutional Support: Technology Development Board, Department of Science and Technology
• Products: Allogeneic CAR-NK and CAR-gamma delta T cell therapy platforms, all pre-clinical

The Innovation: Allogeneic Cell Therapy

Cell therapy has revolutionized cancer treatment, yet its high cost and personalized manufacturing make it inaccessible for many. East Ocyon Bio addresses this challenge with allogeneic cell therapy, which uses cells from healthy donors engineered to target specific cancer cells.

CAR-NK Therapy involves natural killer cells modified with a chimeric antigen receptor (CAR) to attack cancer cells. This method promises to be safer and more scalable than traditional CAR-T therapy, which can cause severe immune reactions.

Funding and Support

In December 2024, East Ocyon Bio secured $4.2 million in seed funding co-led by Aeravti Ventures and Micro Labs. This investment aims to fund pre-clinical testing, establish a GMP-compliant facility, and initiate Phase I clinical trials.

Government Grants

In February 2026, the Technology Development Board under the Department of Science and Technology provided financial assistance for East Ocyon Bio's project titled 'CAR-NK based Cell Therapy Development and Clinical Trials for Difficult-to-treat Tumours and Leishmaniasis.' The grant aims to create a platform-based ecosystem for off-the-shelf CAR-NK therapies, reducing India's reliance on imported treatments.

Future Prospects

East Ocyon Bio's vision is to develop curative treatments for cancers, autoimmune disorders, and rare diseases, all designed and tested domestically. The company's focus on synthetic biology and non-viral cell engineering positions it as a leader in the field of allogeneic cell therapy.

FAQs

**Q1: What is allogeneic cell therapy? **A1: Allogeneic cell therapy uses cells from healthy donors engineered to target specific cancer cells, offering a scalable and potentially safer alternative to personalized CAR-T therapy.

**Q2: How much funding did East Ocyon Bio raise? **A2: East Ocyon Bio raised $4.2 million in seed funding in December 2024.

**Q3: What government support has East Ocyon Bio received? **A3: In February 2026, East Ocyon Bio received financial assistance from the Technology Development Board for its CAR-NK therapy project.

Conclusion

East Ocyon Bio is poised to revolutionize cancer treatment in India with its innovative allogeneic cell therapy. With substantial funding, government support, and a strong team, the company is set to bridge the gap in access to advanced medical treatments.

Call-to-Action

For more information on East Ocyon Bio and their groundbreaking work in cell therapy, visit blogy.in.